로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Cell > NKp46 > CHEK-ATP153

HEK293/Human NKp46 Stable Cell Line

  • Description
    HEK293/Human NKp46 Stable Cell Line
  • Application

    Binding assay by FACS and cell based ELISA.

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (10 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    10% DMSO + 90% FBS
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Receptor Assay
 NKp46 FACS

Fig. FACS analysis of NKp46 on HEK293/Human NKp46 Stable Cell Line.
FACS assay shows that Biotinylated anti-NKP46, Human IgG1 | Human Kappa can bind to HEK293/Human NKp46 Stable Cell Line. HEK293/Human NKp46 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Please contact us if you are interested in related cell pool service.

  • Background
    Natural cytotoxicity triggering receptor 1 (NCR1) is also known as Natural killer cell p46-related protein (NK-p46), Lymphocyte antigen 94 homolog (LY94), CD antigen CD335, which belongs to the natural cytotoxicity receptor (NCR) family. NCR1 contains two Ig-like (immunoglobulin-like) domains. NCR1 interacts with CD247 and FCER1G. NCR1 / CD335 may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.
  • Permits & Restrictions
    This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

코멘트 (0)


재고상품 출발날짜: 영업일 기준 4일

가격(KRW) : 5,250,000

보급 및 전시



약물 개발 현황

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase 2 Clinical

Datasheet & Documentation

관련 제품

신제품

문의와 컨텐츠

This web search service is supported by Google Inc.

totop